 Richard Tobin
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 11 | 2026 | 761 | 2.250 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 72 | 2.230 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2025 | 364 | 1.110 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 5 | 2024 | 37 | 0.890 |
Why?
| | Skin Neoplasms | 4 | 2024 | 847 | 0.850 |
Why?
| | Anus Neoplasms | 1 | 2024 | 32 | 0.820 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 37 | 0.800 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 158 | 0.740 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 100 | 0.710 |
Why?
| | Tretinoin | 2 | 2023 | 124 | 0.710 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 162 | 0.700 |
Why?
| | Ipilimumab | 2 | 2019 | 40 | 0.590 |
Why?
| | Lymphocyte Activation | 5 | 2025 | 1126 | 0.570 |
Why?
| | Tumor Escape | 2 | 2017 | 49 | 0.520 |
Why?
| | Neoplasms | 3 | 2024 | 2884 | 0.480 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 199 | 0.470 |
Why?
| | B-Lymphocytes | 5 | 2025 | 877 | 0.450 |
Why?
| | Lysophospholipids | 2 | 2026 | 77 | 0.420 |
Why?
| | Neurodegenerative Diseases | 2 | 2026 | 151 | 0.410 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 415 | 0.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1958 | 0.380 |
Why?
| | Brain Injuries, Traumatic | 3 | 2024 | 441 | 0.360 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2026 | 917 | 0.320 |
Why?
| | Brain Injuries | 1 | 2014 | 508 | 0.300 |
Why?
| | Uveal Neoplasms | 2 | 2026 | 16 | 0.290 |
Why?
| | Pre-Eclampsia | 3 | 2017 | 205 | 0.280 |
Why?
| | Brain | 2 | 2026 | 2941 | 0.280 |
Why?
| | Spleen | 4 | 2022 | 508 | 0.270 |
Why?
| | Immunity, Innate | 3 | 2025 | 846 | 0.250 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2026 | 53 | 0.240 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 154 | 0.240 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 76 | 0.240 |
Why?
| | Data Curation | 1 | 2026 | 21 | 0.230 |
Why?
| | Antigen Presentation | 2 | 2025 | 205 | 0.230 |
Why?
| | T-Lymphocytes | 4 | 2024 | 1982 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 40 | 0.230 |
Why?
| | Cerebrovascular Disorders | 1 | 2026 | 103 | 0.230 |
Why?
| | Toll-Like Receptor 9 | 1 | 2025 | 37 | 0.220 |
Why?
| | Dementia | 2 | 2026 | 304 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 94 | 0.220 |
Why?
| | Natural Language Processing | 1 | 2026 | 103 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2024 | 2185 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 15 | 0.220 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 134 | 0.210 |
Why?
| | Cell Movement | 2 | 2025 | 965 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 57 | 0.210 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 221 | 0.200 |
Why?
| | Mucous Membrane | 1 | 2024 | 127 | 0.200 |
Why?
| | Neuroimaging | 1 | 2026 | 292 | 0.200 |
Why?
| | Nervous System Diseases | 1 | 2026 | 284 | 0.190 |
Why?
| | Interleukin-4 | 2 | 2014 | 206 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 735 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 272 | 0.190 |
Why?
| | Myocarditis | 1 | 2024 | 102 | 0.190 |
Why?
| | Vagotomy | 1 | 2022 | 33 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 286 | 0.190 |
Why?
| | Mice, Inbred C57BL | 9 | 2026 | 5997 | 0.190 |
Why?
| | Animals | 21 | 2026 | 38109 | 0.190 |
Why?
| | Capillary Permeability | 2 | 2013 | 134 | 0.180 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2197 | 0.180 |
Why?
| | Humans | 27 | 2026 | 144957 | 0.180 |
Why?
| | Mice | 14 | 2026 | 18365 | 0.180 |
Why?
| | Lymphocytes | 2 | 2020 | 382 | 0.170 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2020 | 12 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 668 | 0.160 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 469 | 0.150 |
Why?
| | Splenectomy | 1 | 2020 | 65 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1134 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 783 | 0.150 |
Why?
| | Cytokines | 3 | 2016 | 2065 | 0.150 |
Why?
| | Renal Circulation | 1 | 2019 | 75 | 0.150 |
Why?
| | Signal Transduction | 7 | 2026 | 5233 | 0.150 |
Why?
| | Haploinsufficiency | 1 | 2019 | 55 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 657 | 0.140 |
Why?
| | Interleukin-10 | 2 | 2025 | 310 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 104 | 0.140 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 863 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Monocytes | 2 | 2020 | 538 | 0.130 |
Why?
| | Inflammation | 5 | 2016 | 2880 | 0.130 |
Why?
| | Peritoneal Diseases | 1 | 2016 | 3 | 0.130 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3550 | 0.130 |
Why?
| | Granulocytes | 1 | 2017 | 80 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 241 | 0.130 |
Why?
| | Histamine | 1 | 2016 | 53 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 988 | 0.120 |
Why?
| | Fas Ligand Protein | 2 | 2015 | 60 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 211 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4569 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 226 | 0.120 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 50 | 0.120 |
Why?
| | fas Receptor | 2 | 2015 | 92 | 0.120 |
Why?
| | Scotland | 2 | 2026 | 23 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1462 | 0.120 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 25 | 0.120 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 389 | 0.110 |
Why?
| | Homeostasis | 1 | 2019 | 640 | 0.110 |
Why?
| | Mast Cells | 1 | 2016 | 146 | 0.110 |
Why?
| | Caspase 3 | 2 | 2013 | 238 | 0.110 |
Why?
| | Microvessels | 2 | 2013 | 99 | 0.110 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2026 | 40 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 68 | 0.110 |
Why?
| | Endothelium, Vascular | 4 | 2014 | 965 | 0.110 |
Why?
| | Lyme Disease | 1 | 2015 | 58 | 0.100 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 194 | 0.100 |
Why?
| | Male | 13 | 2026 | 72406 | 0.100 |
Why?
| | Adaptive Immunity | 1 | 2014 | 169 | 0.100 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 233 | 0.100 |
Why?
| | Staurosporine | 1 | 2013 | 22 | 0.100 |
Why?
| | NF-kappa B | 1 | 2016 | 662 | 0.090 |
Why?
| | bcl-X Protein | 1 | 2012 | 45 | 0.090 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2012 | 68 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2014 | 255 | 0.090 |
Why?
| | Blood Pressure | 2 | 2019 | 1769 | 0.090 |
Why?
| | Fetal Blood | 1 | 2014 | 342 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2015 | 499 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2026 | 3125 | 0.080 |
Why?
| | Apoptosis | 3 | 2015 | 2430 | 0.080 |
Why?
| | Shock, Hemorrhagic | 1 | 2013 | 201 | 0.080 |
Why?
| | Aged | 5 | 2026 | 25947 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 511 | 0.080 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2024 | 39 | 0.080 |
Why?
| | Infant, Premature | 1 | 2014 | 611 | 0.070 |
Why?
| | Female | 10 | 2026 | 78376 | 0.070 |
Why?
| | Middle Aged | 5 | 2026 | 35928 | 0.070 |
Why?
| | Fetal Growth Retardation | 1 | 2014 | 587 | 0.070 |
Why?
| | Inflammation Mediators | 3 | 2016 | 509 | 0.070 |
Why?
| | Rats | 4 | 2019 | 5614 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2017 | 4155 | 0.060 |
Why?
| | Atrophy | 1 | 2026 | 201 | 0.060 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2025 | 113 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 970 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 931 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1385 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 42 | 0.050 |
Why?
| | Presenilin-1 | 1 | 2024 | 33 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2014 | 1173 | 0.050 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2024 | 64 | 0.050 |
Why?
| | Adult | 4 | 2024 | 40506 | 0.050 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 28 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 129 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2026 | 379 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 107 | 0.050 |
Why?
| | Meninges | 1 | 2024 | 49 | 0.050 |
Why?
| | Sirolimus | 1 | 2025 | 281 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 621 | 0.050 |
Why?
| | Proteinuria | 2 | 2014 | 102 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 356 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 695 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2024 | 437 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 311 | 0.050 |
Why?
| | Vagus Nerve | 1 | 2022 | 91 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 444 | 0.040 |
Why?
| | Epilepsy | 1 | 2026 | 387 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 434 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 674 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2026 | 367 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8279 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2540 | 0.040 |
Why?
| | Nerve Degeneration | 1 | 2020 | 48 | 0.040 |
Why?
| | Gestational Age | 2 | 2014 | 975 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 96 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 83 | 0.040 |
Why?
| | Cyclic N-Oxides | 1 | 2019 | 33 | 0.040 |
Why?
| | Nephrons | 1 | 2019 | 23 | 0.040 |
Why?
| | Parkinson Disease | 1 | 2026 | 600 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4109 | 0.040 |
Why?
| | Spin Labels | 1 | 2019 | 59 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 135 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 354 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 836 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Astrocytes | 1 | 2020 | 224 | 0.040 |
Why?
| | Vasoconstriction | 1 | 2019 | 217 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2024 | 622 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3164 | 0.030 |
Why?
| | Pregnancy | 3 | 2017 | 7191 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2026 | 1177 | 0.030 |
Why?
| | Mutation | 2 | 2019 | 4099 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2019 | 276 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1786 | 0.030 |
Why?
| | Cromolyn Sodium | 1 | 2016 | 6 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1500 | 0.030 |
Why?
| | Stroke | 1 | 2026 | 1258 | 0.030 |
Why?
| | Placenta | 2 | 2014 | 780 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 337 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 509 | 0.030 |
Why?
| | Mesentery | 1 | 2016 | 45 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2016 | 268 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 321 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 428 | 0.030 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 63 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2852 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2015 | 12 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.030 |
Why?
| | Triterpenes | 1 | 2015 | 25 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 5965 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2026 | 2738 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 930 | 0.030 |
Why?
| | Borrelia burgdorferi | 1 | 2015 | 21 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 463 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 299 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 57 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 397 | 0.030 |
Why?
| | Fetal Death | 1 | 2014 | 58 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 118 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 127 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 126 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 220 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 80 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 232 | 0.030 |
Why?
| | CD3 Complex | 1 | 2014 | 111 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 17101 | 0.030 |
Why?
| | Lipoproteins | 1 | 2015 | 169 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2014 | 139 | 0.020 |
Why?
| | Necrosis | 1 | 2014 | 244 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2026 | 3869 | 0.020 |
Why?
| | Adherens Junctions | 1 | 2013 | 24 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 202 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2499 | 0.020 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2013 | 83 | 0.020 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 81 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 418 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2013 | 768 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1048 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 324 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1371 | 0.020 |
Why?
| | Birth Weight | 1 | 2014 | 522 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 627 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 260 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1187 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2010 | 198 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1813 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1718 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4275 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 883 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 984 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1264 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 7183 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 7997 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2642 | 0.010 |
Why?
|
|
Tobin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|